Alterations in the NF2/LATS1/LATS2/YAP pathway in Schwannomas

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 10, 2015, Pages 952-959

  Oh, Ji Eun ^a   Ohta, Takashi ^a   Satomi, Kaishi ^a   Foll, Matthieu ^a   Durand, Geoffroy ^a   McKay, James ^a   Le Calvez Kelm, Florence ^a   Mittelbronn, Michel ^b   Brokinkel, Benjamin ^c   Paulus, Werner ^c   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Hippo; LATS1; LATS2; NF2 mutation; Promoter methylation; Schwannoma; YAP

Indexed keywords

LARGE TUMOR SUPPRESSOR HOMOLOGUE 1; LARGE TUMOR SUPPRESSOR HOMOLOGUE 2; NEUROFIBROMATOSIS TYPE 2 PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; HIPPO PROTEIN, HUMAN; LATS1 PROTEIN, HUMAN; LATS2 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; NEURILEMOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; AGED; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, NEUROFIBROMATOSIS 2; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEURILEMMOMA; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84942043831     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000238     Document Type: Article

References (39)

1. Louis DN, Ohgaki H, Wiestler OD, et al., eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC, 2007
2. Lee JD, Kwon TJ, Kim UK, et al. Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas. PLoS One 2012;7:e30418
3. Lassaletta L, Torres-Martin M, Pena-Granero C, et al. NF2 genetic alterations in sporadic vestibular schwannomas: Clinical implications. Otol Neurotol 2013;34:1355-61
4. Hadfield KD, Smith MJ, Urquhart JE, et al. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 2010;29:6216-21
5. Schroeder RD, Angelo LS, Kurzrock R. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: Biologic mechanisms and clinical associations. Oncotarget 2014;5:67-77
6. Kim YH, Ohta T, Oh JE, et al. TP53, MSH4, and LATS1 germline mutations in a family with clustering of nervous system tumors. Am J Pathol 2014;184:2374-81
7. Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 2015;15:73-79
8. Zhao B, Li L, Tumaneng K, et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev 2010;24:72-85
9. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011;13:877-83
10. Johnson R, Halder G. The two faces of Hippo: Targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014;13:63-79
11. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle 2012;11:1090-96
12. Zhao B, Li L, Lei Q, et al. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev 2010;24:862-74
13. Zhang X, Milton CC, Humbert PO, et al. Transcriptional output of the Salvador/warts/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res 2009;69:6033-41
14. Yi C, Shen Z, Stemmer-Rachamimov A, et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal 2013;6:ra77
15. Barron DA, Kagey JD. The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med 2014;3:25
16. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-99
17. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 2011;27:2987-93
18. R Core Team. The R Project for Statistical Computing. Vienna, AT: R Foundation for Statistical Computing, 2014
19. Fox J, Weisberg S. An R Companion to Applied Regression. 2nd ed. Thousand Oaks, CA: Sage, 2011
20. Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164
21. Pruitt KD, Brown GR, Hiatt SM, et al. RefSeq: An update on mammalian reference sequences. Nucleic Acids Res 2014;42:D756-63
22. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-81
23. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-49
24. Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 2012;491:56-65
25. Fu W, O'Connor TD, Jun. G, et al. Analysis of 6, 515 exomes reveals the recent origin of most human protein-coding variants. Nature 2013;493:216-20
26. Badiali M, Gleize V, Paris S, et al. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol 2012;22:841-47
27. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-26
28. Zawlik I, Vaccarella S, Kita D, et al. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: A population-based study. Neuroepidemiology 2009;32:21-29
29. Hall CA, Wang R, Miao J, et al. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 2010;70:8517-25
30. Visser S, Yang X. LATS tumor suppressor: A new governor of cellular homeostasis. Cell Cycle 2010;9:3892-903
31. Yu T, Bachman J, Lai ZC. Mutation analysis of large tumor suppressor genes LATS1 and LATS2 supports a tumor suppressor role in human cancer. Protein Cell 2015;6:6-11
32. Ji T, Liu D, Shao W, et al. Decreased expression of LATS1 is correlated with the progression and prognosis of glioma. J Exp Clin Cancer Res 2012;31:67
33. Jiang Z, Li X, Hu J, et al. Promoter hypermethylation-mediated downregulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006;56:450-58
34. Takahashi Y, Miyoshi Y, Takahata C, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005;11:1380-85
35. Wierzbicki PM, Adrych K, Kartanowicz D, et al. Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. World J Gastroenterol 2013;19:4363-73
36. Hisaoka M, Tanaka A, Hashimoto H. Molecular alterations of h-warts/LATS1 tumor suppressor in human soft tissue sarcoma. Lab Invest 2002;82:1427-35
37. Yabuta N, Mukai S, Okamoto A, et al. N-terminal truncation of Lats1 causes abnormal cell growth control and chromosomal instability. J Cell Sci 2013;126:508-20
38. Yabuta N, Okada N, Ito A, et al. Lats2 is an essential mitotic regulator required for the coordination of cell division. J Biol Chem 2007;282:19259-71
39. Li W, Cooper J, Zhou L, et al. Merlin/NF2 loss-driven tumorigenesis linked to CRL4 (DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 2014;26:48-60